{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T22:28:45Z","timestamp":1783722525403,"version":"3.55.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008593","name":"European Respiratory Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000574","name":"British Thoracic Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000574","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008593","name":"European Respiratory Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001465","name":"American Thoracic Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001465","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007560","name":"Chiesi Farmaceutici","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000574","name":"British Thoracic Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000574","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jaip.2020.06.048","type":"journal-article","created":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T12:19:07Z","timestamp":1594642747000},"page":"3363-3370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Pragmatic Clinical Perspective on Biologics for Severe Refractory Type 2 Asthma"],"prefix":"10.1016","volume":"8","author":[{"given":"Rory","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"RuiWen Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Lipworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2020.06.048_bib1","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jaip.2019.11.009","article-title":"Exacerbation-prone asthma","volume":"8","author":"Denlinger","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.06.048_bib2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaci.2017.12.1009","article-title":"Refractory airway type 2 inflammation in a large subgroup of asthmatic patients treated with inhaled corticosteroids","volume":"143","author":"Peters","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.06.048_bib3","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jaip.2019.11.020","article-title":"Diagnosis and management of T2-high asthma","volume":"8","author":"Coverstone","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.06.048_bib4","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jaip.2019.11.006","article-title":"T2-\u201clow\u201d asthma: overview and management strategies","volume":"8","author":"Fitzpatrick","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.06.048_bib5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaip.2019.11.008","article-title":"Allergic endotypes and phenotypes of asthma","volume":"8","author":"Akar-Ghibril","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.06.048_bib6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jaip.2019.11.024","article-title":"Eosinophilic asthma","volume":"8","author":"Nelson","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.06.048_bib7","doi-asserted-by":"crossref","first-page":"1900108","DOI":"10.1183\/13993003.00108-2019","article-title":"Defining severe obstructive lung disease in the biologic era: an endotype-based approach","volume":"54","author":"Martin","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2020.06.048_bib8","doi-asserted-by":"crossref","first-page":"1701433","DOI":"10.1183\/13993003.01433-2017","article-title":"Un-diagnosing persistent adult asthma","volume":"50","author":"Lipworth","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2020.06.048_bib9","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.jaip.2020.02.036","article-title":"Systematic assessment of difficult-to-treat asthma: principles and perspectives","volume":"8","author":"Hew","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.06.048_bib10","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1183\/09031936.01.00092101","article-title":"The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics","volume":"18","author":"Sol\u00e8r","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2020.06.048_bib11","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2020.06.048_bib12","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2020.06.048_bib13","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s12325-018-0702-4","article-title":"Liberty Asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy\/safety in patients with uncontrolled, moderate-to-severe asthma","volume":"35","author":"Busse","year":"2018","journal-title":"Adv Ther"},{"key":"10.1016\/j.jaip.2020.06.048_bib14","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1080\/02770903.2018.1534967","article-title":"The prevalence and disease burden of severe eosinophilic asthma in Japan","volume":"56","author":"Nagasaki","year":"2019","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.jaip.2020.06.048_bib15","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.jaci.2007.07.056","article-title":"Asthma cases attributable to atopy: results from the Third National Health and Nutrition Examination Survey","volume":"120","author":"Arbes","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.06.048_bib16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jaci.2006.10.025","article-title":"Severe asthma: lessons from the Severe Asthma Research Program","volume":"119","author":"Wenzel","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.06.048_bib17","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/j.jaci.2016.08.048","article-title":"U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics","volume":"139","author":"Lefaudeux","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.06.048_bib18","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jaip.2019.08.050","article-title":"Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma","volume":"8","author":"Corren","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.06.048_bib19","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jaip.2019.11.026","article-title":"Allergic burden and response to dupilumab","volume":"8","author":"Lipworth","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.06.048_bib20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/cea.13310","article-title":"Variability of blood eosinophils in patients in a clinic for severe asthma","volume":"49","author":"Rakowski","year":"2019","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2020.06.048_bib21","first-page":"CD010834","article-title":"Anti-IL5 therapies for asthma","volume":"9","author":"Farne","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaip.2020.06.048_bib22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1034\/j.1399-3003.1999.14a06.x","article-title":"What are minimal important changes for asthma measures in a clinical trial?","volume":"14","author":"Santanello","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2020.06.048_bib23","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.rmed.2004.10.008","article-title":"Measurement properties and interpretation of three shortened versions of the asthma control questionnaire","volume":"99","author":"Juniper","year":"2005","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2020.06.048_bib24","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/intimm\/dxp102","article-title":"IL-5- and eosinophil-mediated inflammation: from discovery to therapy","volume":"21","author":"Kouro","year":"2009","journal-title":"Int Immunol"},{"key":"10.1016\/j.jaip.2020.06.048_bib25","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2020.06.048_bib26","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts","volume":"150","author":"Corren","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2020.06.048_bib27","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2020.06.048_bib28","doi-asserted-by":"crossref","first-page":"1902420","DOI":"10.1183\/13993003.02420-2019","article-title":"Mepolizumab effectiveness and identification of super-responders in severe asthma","volume":"55","author":"Harvey","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2020.06.048_bib29","first-page":"CD003559","article-title":"Omalizumab for asthma in adults and children","author":"Normansell","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaip.2020.06.048_bib30","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.anai.2018.01.030","article-title":"Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma","volume":"120","author":"Chipps","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.06.048_bib31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","article-title":"Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies","volume":"6","author":"FitzGerald","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2020.06.048_bib32","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1164\/rccm.201903-0599LE","article-title":"Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma: a post hoc analysis","volume":"200","author":"Shrimanker","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2020.06.048_bib33","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S2213-2600(18)30201-7","article-title":"Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial","volume":"6","author":"Russell","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2020.06.048_bib34","doi-asserted-by":"crossref","first-page":"2000117","DOI":"10.1183\/13993003.00117-2020","article-title":"Sub-optimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena","volume":"56","author":"Mukherjee","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2020.06.048_bib35","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2213-2600(18)30184-X","article-title":"Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials","volume":"6","author":"Panettieri","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2020.06.048_bib36","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2213-2600(16)30265-X","article-title":"Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials","volume":"4","author":"Hanania","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2020.06.048_bib37","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/S2213-2600(18)30275-3","article-title":"Anti-interleukin 13 for asthma: stick or twist?","volume":"6","author":"Lipworth","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2020.06.048_bib38","author":"Bateman"},{"key":"10.1016\/j.jaip.2020.06.048_bib39","doi-asserted-by":"crossref","first-page":"1702523","DOI":"10.1183\/13993003.02523-2017","article-title":"Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study","volume":"51","author":"Humbert","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2020.06.048_bib40","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.rmed.2007.01.011","article-title":"Predicting and evaluating response to omalizumab in patients with severe allergic asthma","volume":"101","author":"Bousquet","year":"2007","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2020.06.048_bib41","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2020.06.048_bib42","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.jaci.2006.09.007","article-title":"Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis","volume":"118","author":"Stein","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.06.048_bib43","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2019.09.042","article-title":"Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaip.2020.06.048_bib44","doi-asserted-by":"crossref","first-page":"1800936","DOI":"10.1183\/13993003.00936-2018","article-title":"Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma","volume":"52","author":"Bleecker","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2020.06.048_bib45","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.jaip.2020.01.009","article-title":"Disconnect between effects of mepolizumab on severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps","volume":"8","author":"Chan","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.06.048_bib46","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2020.06.048_bib47","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2020.06.048_bib48","first-page":"804","article-title":"Efficacy of dupilumab in different racial subgroups of adults with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials","volume":"18","author":"Alexis","year":"2019","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.jaip.2020.06.048_bib49","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2020.06.048_bib50","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1164\/rccm.9120-11ST","article-title":"An Official ATS Clinical Practice Guideline: interpretation of exhaled nitric oxide levels (FeNO) for clinical applications","volume":"184","author":"Dweik","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2020.06.048_bib51","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.rmed.2019.07.010","article-title":"Scottish consensus statement on the role of FeNO in adult asthma","volume":"155","author":"Kuo","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2020.06.048_bib52","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.rmed.2019.04.017","article-title":"Association between exhaled nitric oxide and nasal polyposis in severe asthma","volume":"152","author":"Maniscalco","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2020.06.048_bib53","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2020.06.048_bib54","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1378\/chest.12-1310","article-title":"Inhaled corticosteroid dose response using domiciliary exhaled nitric oxide in persistent asthma: the FENOtype trial","volume":"142","author":"Anderson","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2020.06.048_bib55","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1164\/rccm.201806-1182OC","article-title":"Remotely monitored therapy and nitric oxide suppression identifies nonadherence in severe asthma","volume":"199","author":"Heaney","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2020.06.048_bib56","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jaci.2014.09.034","article-title":"High blood eosinophil counts predict sputum eosinophilia in patients with severe asthma","volume":"135","author":"Fowler","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.06.048_bib57","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S2213-2600(15)00419-1","article-title":"Blood or sputum eosinophils to guide asthma therapy?","volume":"3","author":"Mukherjee","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2020.06.048_bib58","doi-asserted-by":"crossref","first-page":"2000104","DOI":"10.1183\/13993003.00104-2020","article-title":"Systemic potency of fluticasone in asthma","volume":"55","author":"Lipworth","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2020.06.048_bib59","first-page":"A95","article-title":"P13 Exhaled nitric oxide and blood eosinophil count in predicting sputum inflammatory type in a heterogeneous airways disease population","volume":"74","author":"Lehtim\u00e4ki","year":"2019","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2020.06.048_bib60","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13223-018-0248-7","article-title":"Association between fractional exhaled nitric oxide, sputum induction and peripheral blood eosinophil in uncontrolled asthma","volume":"14","author":"Gao","year":"2018","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2020.06.048_bib61","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.chest.2019.02.403","article-title":"CT and functional MRI to evaluate airway mucus in severe asthma","volume":"155","author":"Svenningsen","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2020.06.048_bib62","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaci.2018.08.031","article-title":"Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: indirect treatment comparison","volume":"143","author":"Busse","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.06.048_bib63","doi-asserted-by":"crossref","first-page":"1801393","DOI":"10.1183\/13993003.01393-2018","article-title":"Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review","volume":"52","author":"Bourdin","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2020.06.048_bib64","first-page":"A36","article-title":"S53 Response to benralizumab after sub-optimal response to mepolizumab in severe eosinophilic asthma","volume":"74","author":"Kavanagh","year":"2019","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2020.06.048_bib65","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N\u00a0Engl J Med"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219820306887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219820306887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:27:07Z","timestamp":1761974827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219820306887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":65,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S2213219820306887"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2020.06.048","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pragmatic Clinical Perspective on Biologics for Severe Refractory Type 2 Asthma","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2020.06.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}